Oxidative stress is important in several pathologies, including cardiovascular diseases such as atherosclerosis and cardiac ischemia-reperfusion injury. An important mechanism for adaptation to oxidative stress is induction of genes through the antioxidant response element (ARE), which regulates the expression of antioxidant and cytoprotective genes via the transcription factor Nrf2 (nuclear factor E2-related factor 2). As Nrf2-regulated genes are induced during oxidant stress occurring, for example, in reperfusion after ischemia, we took a novel approach to exploit ARE for the development of oxidative stress-inducible gene therapy vectors. To this end, one, two or three ARE-containing regions from human NAD(P)H:quinone oxidoreductase-1, glutamate-cysteine ligase modifier subunit and mouse heme oxygenase-1 were cloned into a vector expressing luciferase under a minimal SV40 promoter. The construct, which was the most responsive to ARE-inducing agents, was chosen for further studies in which a lentiviral vector was produced for an efficient transfer to endothelial cells. Heme oxygenase-1 (HO-1), which has well-characterized anti-inflammatory properties, was used as the therapeutic transgene. In human endothelial cells, AREdriven HO-1 overexpression inhibited nuclear factor-kB activation and subsequent vascular cell adhesion molecule-1 expression induced by tumor necrosis factor-a. We conclude that the ARE element is a promising alternative for the development of oxidative stress-inducible gene therapy vectors.
Introduction
Oxidative stress, an imbalance between the production and disposal of reactive oxygen species (ROS), has been implicated to be important in the development of several cardiovascular diseases (CVDs), including atherosclerosis, restenosis and ischemia-reperfusion (I/R) injury. ROS and oxidation products of macromolecules such as lipids have a wide spectrum of effects, which may lead to exacerbation of pathophysiological processes. 1, 2 Thus, counterbalancing oxidative processes by supporting antioxidant defense may provide means to ameliorate these pathologies. Of note, several antioxidant genes such as extracellular superoxide dismutase and heme oxygenase-1 (HO-1) have been used for gene therapy in experimental animal models of CVD. 3 Heme oxygenase-1 has well-documented protective effects in the vasculature (reviewed in Stocker and Perrella 4 and Ryter et al.
5
). It is the rate-limiting enzyme of heme catabolism, in which heme is degraded to carbon monoxide (CO) and biliverdin. Biliverdin is further metabolized to bilirubin, a powerful antioxidant.
The protective effects of HO-1 have been assigned to both CO and bilirubin. 3, 6 Both of these can exert their effects in the vasculature through multiple mechanisms (for example, by inhibition of vascular smooth muscle proliferation, promotion of vessel relaxation and inhibition of inflammation). Overexpression of HO-1 or the administration of CO is anti-inflammatory via suppression of proinflammatory cytokines and promotion of the expression of the anti-inflammatory interleukin-10. In endothelial cells, adenoviral overexpression of HO-1 has been shown to inhibit tumor necrosis factor (TNF)-a-induced activation of nuclear factor (NF)-kB and vascular cell adhesion molecule-1 (VCAM-1) expression. 7, 8 For an optimal therapeutic response, it would be beneficial if the transgene expression could be regulated in order to turn the gene expression on and off when needed. This can be accomplished through the use of promoters that can be activated by orally administered drugs, such as tetracycline. 9 An alternative strategy, circumventing the timing problem related to the use of vectors regulated by exogenous agents is to use vectors activated by an endogenous, pathophysiological stimulus, such as hypoxia or oxidative stress. Hypoxiaregulated gene therapy vectors using tandem repeats of hypoxia response elements (HREs), enhancer regions in the promoters of genes activated during hypoxia, have been developed and used to regulate expression of the HO-1 transgene in vectors used for cardioprotection against I/R injury. 10, 11 By analogy, vectors that would physiologically respond to oxidative stress could be useful for gene therapy in pathologies in which ROS are important.
During oxidative stress, a number of cytoprotective genes are transcriptionally induced through the antioxidant response element (ARE), a cis-acting sequence in their promoters. 12 The consensus core ARE-sequence TGAC/GnnnGC binds basic leucine zipper (bZIP) transcription factors, most notably nuclear factor E2-related factor 2 (Nrf2), which forms heterodimers with other bZIP factors, such as small Maf proteins. 13, 14 Under basal conditions, Nrf2 is repressed by Kelch-like ECHassociated protein 1, which facilitates proteasomal degradation of Nrf2 through Cullin-3-dependent ubiquitin ligase complex. During oxidative stress, Nrf2 escapes proteasomal degradation machinery, translocates to the nucleus and activates target gene expression via binding to ARE. 15 Agents which activate ARE include heavy metals, heme, ultraviolet irradiation and oxidized lipids. 12, 16, 17 A number of ARE target-genes encoding antioxidant or phase II detoxification genes have been characterized. These include glutamate-cysteine ligase, the rate-limiting enzyme of glutathione synthesis, which consists of catalytic and modifier (GCLM) subunits, HO-1 and NAD(P)H:quinone oxidoreductase-1 (NQO1).
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The aim of this study was to assess whether the ARE sequence can be utilized to develop gene therapy vectors regulated by oxidative stress. We first screened the activity of AREs from three separate genes by cloning them into a luciferase-reporter plasmid and testing the induction of these constructs by different activating agents in human cell lines in vitro. The best constructs were cloned to a lentiviral vector for better transduction efficiency in human primary endothelial cells. We also produced a lentiviral vector expressing a therapeutic gene (HO-1) under ARE, and examined whether it could reduce TNF-a-induced vascular inflammation assessed by NF-kB activation and VCAM-1 expression.
Results

Developing and testing of oxidative stress-inducible plasmid constructs
To study whether AREs can be used to develop oxidative stress-inducible promoters, we chose three well-characterized ARE-regulated genes from which we cloned ARE-containing promoter regions into a luciferasereporter vector, upstream of a minimal SV40 promoter ( Figure 1 ). These genes were human NQO1, human GCLM and mouse heme oxygenase-1 (mHO-1). In order to study basal and inducible expression, plasmid constructs were transfected into 293T cells and oxidative stress was evoked with diethyl maleate (DEM). DEM is an electrophilic compound that depletes cellular glutathione thereby producing oxidative stress. It is also a well-known inducer of the ARE response. 12 Exposure to DEM resulted in a 2.5-to 4.1-fold increase in luciferase activity in 293T cells transfected with ARE-regulated plasmid vectors (Figure 2a) . The highest inductions in 293T cells were obtained with constructs having either NQO1 or GCLM inserts. All ARE-containing constructs showed basal transcriptional activity. With increasing number of inserts, there was an increase in basal
expression. An addition of a third insert did not yield any additional increase in the inducible expression (Figure 2a ). On the basis of these results, we chose luciferase constructs having 1 Â NOQ1, 2 Â NQO1, 1 Â GCLM and 2 Â GCLM for further analysis and examined the direct effect of Nrf2 overexpression on the luciferase activity. Nrf2 overexpression through cotransfection of an Nrf2-overexpressing plasmid increased the activity of these constructs up to 4.4-fold (Figure 2b ).
We also tested 1 Â NQO1, 2 Â NQO1, 1 Â GCLM and 2 Â GCLM constructs in human umbilical endothelial vein cells (HUVECs) in a similar manner, using 15-deoxy-prostaglandin J 2 (15d-PGJ 2 ) as an activator (Figure 2c ). 17 15d-PGJ 2 is a lipid oxidation product derived from the cyclooxygenase pathway, and it has been shown to be produced during inflammation 22 and shear stress. 23, 24 It is also a potent inducer of Nrf2. 17, 19 In HUVECs, the reporter gene expression of all constructs was increased by 15d-PGJ 2 ( Figure 2c ). Similar to 293T cells, the basal luciferase activity was higher when the number of inserts was increased.
Induction of lentiviral ARE constructs in HUVECs
Based on results obtained with plasmid transfections, 1 Â NQO1, 2 Â NQO1, 1 Â GCLM and 2 Â GCLM constructs were cloned into a lentiviral vector for a more efficient gene transfer. Lentiviruses effectively transduce human endothelial cells, yielding over 98% efficiency at multiplicities of infection (MOI) 5, assessed by green fluorescent protein (GFP) positivity of cells transduced with GFP-expressing lentivirus and fluorescence-activated cell sorting analysis (results not shown). On the basis of these results, MOI 5 was used for lentiviral transduction of HUVECs. The activity of all constructs was increased on exposure to 15d-PGJ 2 , the induction being the greatest, B10-fold, with 2 Â GCLM-luc construct ( Figure 3) .
It has been noted that when HRE-regulated vectors are delivered into cells and induced by hypoxia, the Figure 1 Antioxidant response element (ARE)-containing sequences used in the study. One, two or three promoter fragments were cloned in tandem into the pGL3-promoter vector upstream of the SV40 minimal promoter. From human NAD(P)H:quinone oxidoreductase-1 (NQO1), 30 bp long promoter region which contains one ARE (underlined), from human glutamate-cysteine ligase modifier (GCLM), subunit 50 bp long promoter region having two AREs and from mouse heme oxygenase-1 (mHO-1), 268 bp long promoter region containing three stress response elements (StREs, similar to AREs) were used.
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H Hurttila et al induction of the endogenous hypoxia-regulated genes is impaired. This is likely due to the 'decoy' effect of the overexpressed HRE element. 25 We therefore tested (a) ARE-constructs were transfected into 293T cells and exposed to 200 mM DEM after transduction. Luciferase activities were normalized to b-galactosidase activities, and depicted relative to control (empty pGL3-promoter vector; n ¼ 3, mean±s.e.m.) (b) 1 Â glutamate-cysteine ligase modifier (GCLM), 2 Â GCLM, 1 Â NAD(P)H:quinone oxidoreductase-1 (NQO1) and 2 Â NQO1 constructs were co-transfected with nuclear factor E2-related factor 2 (Nrf2) overexpressing plasmid for 48 h.
(n ¼ 4, mean±s.e.m.) (c) 1Â GCLM, 2 Â GCLM, 1 Â NQO1 and 2 Â NQO1 constructs were transfected into HUVECs. The next day, 3 mM 15d-PGJ 2 was added and luciferase activities were measured 24 h later and normalized to b-galactosidase activities. (n ¼ 4, mean ± s.e.m.). All changes in relative luciferase activity between control and induced conditions in a-c were statistically significant (Po0.05). In order to elucidate whether the ARE element can be used to drive a therapeutic transgene, hHO-1 gene was cloned into the 2 Â GCLM lentiviral vector to replace the luciferase gene. The efficacy of the vector to drive hHO-1 expression was assessed by transducing HUVECs and exposing them to 1-5 mM 15d-PGJ 2 . Endogenous hHO-1 mRNA was induced in all cells, including nontransduced cells and cells transduced with control 2 Â GCLM-luc vector. However, hHO-1 was expressed significantly more in cells transduced with HO-1-expressing vector in comparison to either nontransduced or 2 Â GCLM-luctransduced controls. The most significant differences in the mRNA expression (B4.5-fold) were obtained with 3 and 5 mM 15d-PGJ 2 ( Figure 5a ). The HO-1 protein expression was also increased (Figure 5b ).
Lentiviral transduction of ARE-HO-1 decreases the induction of NF-kB and VCAM-1 expression by TNF-a
In endothelial cells, HO-1 has been shown to inhibit the expression of proinflammatory genes, such as VCAM-1 and E selectin, through inhibition of NF-kB. 7, 8 In order to assess if ARE-driven HO-1 expression can have antiinflammatory effects in endothelial cells, we first examined its effect on NF-kB activation assessed by the activation of the NF-kB-regulated luciferase-reporter construct. To this end, cells were transduced with either an empty lentiviral control vector having only the phosphoglycerate kinase (PGK) promoter but no transgene, or 2 Â GCLM-HO-1 vector together with the NFkB-luciferase-reporter construct. TNF-a caused a robust increase in NF-kB activity in both control as well as 2 Â GCLM-HO-1-transduced cells (Figure 6a ). There was a reduction in TNF-a-induced NF-kB activation in 2-GCLM-HO-1 transduced cells without 15d-PGJ 2 ; however, the change was not statistically significant (P ¼ 0.15). When cells were exposed to 15d-PGJ 2 prior to treatment with TNF-a, there was a reduction in NF-kB activity in both control as well as 2 Â GCLM-HO-1-transduced cells. However, the reduction was significantly greater in the latter (57 ± 8% in controls vs 83 ± 6% in 2 Â GCLM-HO-1-transduced controls, Po0.01). In line with these results, HUVECs that were transduced with the 2 Â GCLM-HO-1 lentiviral vector and treated with 15d-PGJ 2 prior to exposure to TNF-a had a significantly greater decrease in VCAM-1 protein expression than controls transduced with 2 Â GCLM-luc control, assessed by densitometric analysis of the western data (Figure 6b ). The effect of 15d-PGJ 2 on TNF-a-induced NF-kB activation and VCAM-1 expression in control cells is likely mediated by the induction of the endogenous HO-1 as well as HO-1 independent NF-kB inhibitory mechanisms.
Discussion
Increased production of ROS is important in a number of CVDs and also during complications of therapeutic interventions such as restenosis after balloon angioplasty and stenting. [1] [2] [3] Counterbalancing the effects of ROS using antioxidant gene transfer for therapy has been shown to be effective in several experimental animal models of cardiovascular pathologies associated with increased radical production. 3 Transfer of therapeutic genes with traditional gene therapy vectors brings on continuous expression of genes, which may be disadvantageous when antioxidant genes are concerned, as ROS mediate also physiological cell signaling processes. 3, 26 Regulatable vectors offer a solution to this problem, especially if they can be regulated by endogenous stimuli relevant to the pathology. Hypoxiaactivated adeno-associated virus (AAV) vector-expressing HO-1 has been developed and successfully used for treatment of cardiac I/R injury, 10 and HO-1 gene transfer also offers protection against chronic recurrent I/R injury and prevents post-infarction heart failure.
10,27,28 AREregulated gene transcription has been shown to be a central mechanism providing protection against oxidative stress in the cardiovascular system. [29] [30] [31] Oxidized low density lipoprotein and 15d-PGJ 2 , agents that are important in vascular inflammatory processes such as atherogenesis and are present in atherosclerotic lesions, 22, 32 are also potent instigators of ARE activation, 17, 33 suggesting that vascular inflammatory processes could be targets for ARE-regulated gene therapy. In addition, in I/R injury, activation of Nrf2 during reperfusion mediates cytoprotective gene expression, 34 implying that ARE-regulated vectors could also be used for attenuation of reperfusion injury.
In order to develop ARE-regulated gene therapy vectors, we chose ARE elements from three wellcharacterized ARE-driven genes, hNQO1, hGCLM and 
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H Hurttila et al mHO-1, and cloned 1-3 inserts in tandem to the luciferase expression vector (Figure 1 ). In human cell line 293T, constructs containing AREs from hNQO1 or hGCLM appeared to be more active than mHO-1 constructs. The mHO-1 gene was chosen for cloning, because the mouse gene has been more extensively characterized. It has two distal enhancer regions (E1 and 2) located approximately À4 and À10 kb relative to the transcriptional start site, respectively. 5 The Proximal E1 fragment used in this study has three well-characterized stress response elements (StRE), structurally and functionally similar to AREs. Although some differences between the regulation of mouse and human genes exist, these StRE are highly conserved between the species and bind similarly transcription factors, for example, Nrf2. Moreover, factors involved in ARE activation are highly homologous, thereby allowing cross-species activation of ARE-containing vectors. 35 It is therefore unlikely that AREs from the mouse gene would be functionally impaired in human cells thereby explaining the differences in activity. Conversely, vectors having ARE sequences derived from human genes are likely to be functional in cells derived form other species allowing the use of these in animal models of CVD.
With all ARE-reporter constructs used in this study, there was a certain level of basal luciferase activity. Normal cell respiration produces ROS and oxidation products of macromolecules, which likely account for this basal activity and thus cannot be avoided. ARE is also shown to regulate basal transcription of hNQO1 and hGCLM genes. 21, 36 For these reasons, it seems unlikely that ARE sequences could be exploited in such a manner that there would be no basal transcriptional activity. Nevertheless, without the inducing agent, the HO-1 expression in cells transduced with 2 Â GCLM-HO-1 lentiviral vector was minimal at both mRNA and protein levels ( Figure 5 ). As oxygen tensions in mammalian tissues in vivo are far below 21% oxygen used for cell culture, 37 it is likely that the oxidant burden, and subsequently basal ARE activity, would be lower in an in vivo situation.
In our experiments, 2 Â GCLM-luc lentiviral vector, the promoter of which was used to drive HO-1 transgene, was induced by 10-fold upon exposure to 15d-PGJ 2 ( Figure 3 ). This induction is of the same magnitude as the B8-fold hypoxic induction in the luciferase activity of the AAV construct driven by four tandem repeats of the erythropoietin HRE element subsequently shown in vivo to provide significant protection against I/R injury when driving the HO-1 transgene. 10 Likewise, HRE-regulated AAV-vector having nine copies of erythropoietin HRE elements yielded similar magnitude of induction of LacZ marker gene in vitro (10-to 30-fold depending on the cell type) in hypoxic conditions. 38 This vector was also shown to effectively increase the expression of vascular endothelial growth factor-A (VEGF-A) transgene in hypoxic mouse myocardium, despite significant induction of the endogenous mouse VEGF-A. 38 It is therefore plausible that the promoter activities seen in our study are sufficient to produce high enough expression levels for a therapeutic effect in an in vivo setting.
In our study, we chose HO-1 as our therapeutic transgene. HO-1 is a highly inducible enzyme, and endogenous HO-1 expression is increased by a wide variety of stressful stimuli. 5 Nevertheless, HO-1 has been used for gene therapy in several experimental animal models of CVD. 10, 11, 27, 28 In the study by Pachori et al. Oxidative stress-inducible vectors H Hurttila et al significant induction of endogenous HO-1 was observed, yet HRE-regulated HO-1 overexpression provided an additional benefit. In our study, both in controls as well as 2 Â GCLM-HO-1-transduced HUVECs, 15d-PGJ 2 significantly attenuated TNF-a-induced NF-kB activation and VCAM-1 expression, but the effect was greater in HO-1-transduced cells (Figure 6 ). Induction of endogenous HO-1 by 15d-PGJ 2 likely contributes to the effects seen in cells transduced with control virus, but 15d-PGJ 2 also has a direct inhibitory effect on NF-kB, which may also be important. 39 In conclusion, we have shown that ARE sequences can be exploited for the development of oxidative stressinducible gene therapy vectors. Future studies will be directed at testing these in relevant animal models of CVD to assess the in vivo efficacy of this approach.
Materials and methods
Plasmid construction
ARE sequences from hNQO1, 18 hGCLM, 17, 36 and mHO-1 40 promoters were cloned into the pGL3-promoter vector (Promega, Madison, WI, USA) ( Figure 1) . One, two and three inserts were cloned per vector and named as shown in Figure 1 . For cloning of the NQO1 ARE into the pGL3-promoter vector, we designed and annealed oligonucleotides (TAG Copenhagen, Copenhagen, Denmark) (Table 1) containing suitable ends that can be ligated into KpnI-SacI, NheI-XhoI and XhoI-BglII sites in the vector. The ARE region of hGCLM gene was amplified by PCR using primers (TAG Copenhagen) ( Table 1 ) which contained restriction sites for cloning into the same sites as hNQO1 inserts. The promoter region of mHO-1 known as AB1 or SX2 was a kind gift from Dr Jawed Alam (Oschner Clinic, New Orleans, LA, USA). First insert was directly digested with SacI and SpeI from the vector containing full-length AB1/SX2 40 and ligated into SacI-NheI site of pGL3 promoter. Other inserts were PCR amplified using primers (TAG Copenhagen) (Table 1) containing complementary ends for cloning the inserts into KpnI and XhoI-BglII sites of pGL3 promoter.
For cloning of hHO-1 cDNA into the 2 Â GCLM vector, hHO-1 was PCR amplified from hHO-1 cDNA-containing vector, 41 using primers-containing HindIII (sense) and XbaI (antisense) restriction sites (TAG Copenhagen) ( Table 1) . PCR product was cloned into 2 Â GCLM vector replacing the luciferase gene with hHO-1. All constructs were verified by sequencing.
Lentiviral production
From the 1 Â NQO1, 2 Â NQO1, 1 Â GCLM and 2 Â GCLM luciferase constructs as well as the 2 Â GCLM-HO-1 construct, third-generation HIV-1-based lentiviral vectors were produced. ARE elements, minimal SV40 promoter and the luciferase gene were digested with KpnI and XbaI and blunt ligated into the lentiviral backbone. 42 NF-kB-luc-reporter construct was cloned by SphI-HindIII digesting NF-kB elements from pNF-kB-Luc (Stratagene, La Jolla, CA, USA), and blunt ligating into the XhoI site of pGL3 promoter and then cloning NF-kB response elements, minimal SV40 promoter and luciferase gene into the lentiviral backbone as previously described. Also a control lentiviral vector containing only minimal SV40 promoter and luciferase gene was cloned. In addition, a lentiviral vector construct expressing GFP under PGK promoter 43 was used for cloning of a control vector from which the GFP transgene was removed. All constructs were verified by sequencing prior to production using standard methods as in Follenzi and Naldini 44 The titer was assessed by HIV p24 enzyme-linked immunosorbent assay (ELISA) (Perkin Elmer, Waltham, MA, USA). To test transduction efficiency of lentiviruses in HUVECs, lentiviral construct expressing GFP under PGK promoter was used. 43 
Cell culture
Human embryonic kidney 293T cells were purchased from ATCC (Teddington, Middlesex, UK) and were maintained in Dulbecco's modified Eagle's medium 46 Luciferase activities were normalized to b-galactosidase activities or when lentiviral transductions were used, to protein concentrations measured by BCA Protein Assay Kit (Pierce, Rockford, IL, USA) according to manufacturer's instructions.
The effect of Nrf2 overexpression on 1 Â NQO1, 2 Â NQO1, 1 Â GCLM and 2 Â GCLM constructs was studied by co-transfection with pCI-Nrf2 plasmid. 19 For this study, 20 000 293T cells were plated on 96-well plates. The next day, cells were transfected with 45 ng ARE-plasmid construct and 45 ng pCI-Nrf2 or pCDNA3 (Invitrogen). For normalization, cells were also transfected with 10 ng of pCMV-b-gal vector. Forty-eight hours after transfection, luciferase activities were measured with Britelite Reporter Gene Assay (Perkin Elmer) according to manufacturer's instructions. The b-galactosidase activity was measured as previously described.
Analyzing the effect of induced ARE-regulated vectors on endogenous ARE-regulated gene expression
To analyze whether transduction and induction of ARE-regulated vectors affect the expression of endogenous ARE-regulated genes, we plated 150 000 HUVECs on six-well plates. The next day, cells were transduced with SV40-luc control or 2 Â GCLM-luc virus. After 24 h, 5 mM 15d-PGJ 2 was added to cells for 16 h. Protein levels of hHO-1 and hGCLM were analyzed with western blotting using 15 mg of protein for SDS-polyacrylamide gel electrophoresis using reducing conditions. The proteins were transferred to a nitrocellulose membrane, blocked and incubated with primary antibodies. The primary antibodies used were rabbit polyclonal anti-HO-1 (Stressgen, Ann Arbor, MI, USA), anti-GCLM (a gift from Dr Terrance Kavanagh, University of Washington, Seattle, WA, USA) and rabbit polyclonal b-actin (Cell Signaling, Danvers, MA, USA). Blots were visualized using ECL Plus Western blotting Detection System with Typhoon 9400 (GE Healthcare, Buckinghamshire, UK).
Assessment of hHO-1 expression
To analyze the amount of hHO-1 expressed, 150 000 HUVECs were plated on six-well plates. After 24 h, HUVECs were transduced with 2 Â GCLM-luc or with 2 Â GCLM-hHO-1 lentiviral constructs using MOI 5. The next day, 15d-PGJ 2 was added to cells, and cells were collected at 6 h for RNA and 20 h for protein analyses. Total-RNA (1 mg) isolated using TriReagent (Sigma-Aldrich) was used for the cDNA synthesis using random hexamer primers (Promega) and M-MuLV reverse transcriptase (New England Biolabs, Ipswich, MA, USA). Relative expression levels of mRNA encoding hHO-1 or human b-2 microglobulin (hB2M) were measured according to manufacturer's protocol by quantitative RT-PCR (ABI PRISM 7700 Sequence detector, Applied Biosystems, Foster City, CA, USA) using specific Assays-on-Demand (Applied Biosystems) target mixes (Hs00157965 and Hs00187842). The expression levels of hHO-1 were normalized to the levels of hB2M. Western blotting was done as described in the previous section.
Effect of HO-1 induction on NF-kB activation
To assess whether lentiviral ARE-regulated HO-1 expression has an effect on NF-kB activation by TNF-a, HUVECs (15 000 per well) were plated on 96-well plates. The next day, cells were co-transduced with NF-kBluciferase expression vector together with an empty lentiviral vector control (PGK promoter with no transgene) or 2 Â GCLM-HO-1 lentiviral construct. After 16 h, cells were treated with 3 mM 15d-PGJ 2 prior to exposure to hTNF-a (4 ng ml À1 ) (Sigma-Aldrich). After 16 h, luciferase activities and protein concentrations were measured as above.
Effect of HO-1 induction on VCAM-1 expression
To assess whether lentiviral ARE-regulated HO-1 expression affects the induction of adhesion molecule VCAM-1 by TNF-a, 150 000 HUVECs were plated on six-well plates. The next day, cells were transduced with 2 Â GCLM-luc or 2 Â GCLM-HO-1 virus using MOI 5. After 24 h, 5 mM 15d-PGJ 2 was added to cells. The following day, cell culture medium was changed and cells were treated with 4 ng ml hTNF-a (SigmaAldrich). This concentration was chosen on a basis of earlier experiments, in which we tested the effectiveness of 0.1-20 ng ml À1 of TNF-a on activation of NF-kBreporter plasmid and induction of VCAM-1 expression, and saw close to maximal responses in both NF-kB activation as well as VCAM-1 induction at 4 ng ml
À1
. Cells were lysed 6 h later and western blotting was done as above, using rabbit polyclonal VCAM-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) as a primary antibody. Protein expression was quantified with ImageQuant TL 7.0 software (GE Healthcare).
Statistical analyses
Statistical analyses were performed with GraphPad Prism software (GraphPad Software Inc., San Diego, Oxidative stress-inducible vectors H Hurttila et al CA, USA). Results are expressed as mean ± s.e.m. Statistical significance was evaluated by paired t-test, and Po0.05 was considered statistically significant. N denotes the number of independent cell experiments.
